anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Within the context of a pilot randomized controlled trial, the objectives are to: 1. Optimize the content and delivery of the intervention through an iterative series of quality improvement cycles informed by structured feedback from parents, youth, and intervention providers after each session; 2. Field test study logistics, including participant recruitment, willingness to consent to a randomized trial; loss to follow-up; the acceptability and feasibility of the study measures; and 3. Obtain empiric estimates of study parameters to inform future clinical trial design, including within-group standard deviation of continuous measures; correlations of repeated measures; and proportion of control group subjects who experience each outcome. The products at the end of the pilot study will be an optimized intervention model, developed with parent and youth input and ready for efficacy testing; and a set of putative intervention targets ready to be tested in the subsequent trial. The ultimate goal is to develop an effective approach to youth substance use prevention, delivered within the infrastructure of the patient-centered medical home. If successful, this trajectory of work has the potential to identify a novel, family-centered approach to substance use disorder prevention for a high-risk population of youth whose parents are in recovery.
The goal of this proposal is to develop a novel triple-tracer positron emission tomography (PET) method to image in vivo insulin-stimulated tissue perfusion, glucose transport and glucose phosphorylation in skeletal muscle in healthy individuals. The long term goal will be to later apply this model to the study of metabolic diseases, notably type 2 diabetes mellitus (Type 2 DM) and obesity (Ob). While it is often suggested that glucose transport is the rate-controlling step for insulin action, we will test the hypothesis that the control insulin exerts on the uptake of glucose into skeletal muscle is distributed across flow and tissue perfusion, trans-membrane transport and intra-cellular phosphorylation of glucose.

Specific Aim 1. The first specific aim is to develop the triple-tracer PET method for quantitative determinations of tissue perfusion, glucose transport and glucose phosphorylation in skeletal muscle. To measure blood flow and tissue perfusion, we will use 15O-H2O (half-life \~ 2 min; also referred to as 15O-water). To measure glucose transport, we will use 11C-3-O-methyl glucose (half-life \~ 20 min; also referred to as 3-0-MG), an analog that is transported but not phosphorylated or otherwise metabolized. 18F-2-deoxy-2-fluoro-glucose (half-life \~ 109 min; also referred to as FDG), will be used to examine glucose transport and glucose phosphorylation. Because of the differences in half-life of the three positrons (15O, 11C, and 18F), it is feasible to use each of these tracers, in sequence, in the same individual.

Specific Aim 2. The second specific aim is to rigorously test mathematical models to extract quantitative physiological information from dynamic PET imaging. We will test a novel model that specifically addresses the kinetics of substrate delivery within the interstitial space of skeletal muscle (i.e. a 5 rate constant, 4 compartment model with respect to FDG. Model testing will entail use of non-compartmental models e.g. spectral analysis).
Spontaneous coronary artery dissection (SCAD) is an under-diagnosed and poorly understood condition that frequently affects young women without conventional cardiovascular (CV) risk factors and can result in myocardial infarction (MI), cardiac arrest, and death. This condition has not been adequately studied, and there are no randomized controlled trials to guide treatment. Furthermore, SCAD has been frequently misdiagnosed due to the current "gold-standard" coronary angiography limitations. As such, there are uncertainties with the diagnosis and management of SCAD patients. Therefore, the investigators propose a large prospective multicenter Canadian SCAD Study to ascertain the natural history of predisposing arteriopathies and treatment strategy on short and long-term CV outcomes to design future randomized controlled trials.

This is a multicenter, prospective, international, observational natural history study with a planned total enrolment of 3,000 patients with SCAD. The investigators plan to recruit patients from major cardiac catheterization centers across Canada and several centers in the United States and internationally. The research team successfully enrolled 750 patients prospectively in the "Canadian SCAD Cohort Study" from 22 sites in North America. This current study will be an extension of that study, now named the "Canadian SCAD Study." It will continue enrolment for a total of 3,000 patients internationally (from \>35 sites). Detailed baseline demographics, targeted history for precipitating stressors and predisposing conditions, and investigations for predisposing conditions will be performed during the study. Patients will be prospectively followed long-term for up to 10 years for CV events. The study is approved, allowing potential participants to be enrolled using an electronic consent form irrespective of their geographic location and directly communicating with the study team at UBC.
PROBLEM TO BE SOLVED: To obtain a deodorant for garlic which contains a specific deodorant component and can remove or reduce the garlic smell or unpleasant smell after eating garlic. SOLUTION: This deodorant contains a plant of Aspalathus Iinearis (generic name: rooibos crown) containing flavonoids. This component specifically reacts with the sulfur compound which is the bad-smell component in the garlic to deodorize. By the flavonoids from Aspalathus linearis, lower mercaptans, sulfides, disulfides, trisulfides and their decomposition products which causes a variety of unpleasant odors can be readily inhibited whereby the unpleasant smells from garlic can be controlled. The deodorant component is obtained by extracting rooisos crown with cold or warm water. The extract can be processed into a wide range of food products for example, siverberry candies, chewing gum, refreshing drinks and foods.
Mexico is considered one of the countries with the greatest diversity of the Salvia genus. A significant percentage of its species are known for their use in traditional medicine, highlighting their use as an analgesic. The objective of this work was to determine the chemical composition of the methanolic extracts of S. cinnabarina, S. lavanduloides and S. longispicata through untargeted metabolomics, as well as the in vivo evaluation of the antinociceptive effect and acute oral toxicity. The chemical profiling was performed using ultra-high performance liquid chromatography coupled with a high-resolution mass spectrometry (UPLC-ESI+/--MS-QTOF) system and tentative identifications were performed using a compendium of information on compounds previously isolated from Mexican species of the genus. Pharmacological evaluation was carried out using the formalin test and OECD guidelines. The analysis of the spectrometric features of the mass/charge ratios of the three salvias shows that a low percentage of similarity is shared between them. Likewise, the putative identification allowed the annotation of 46 compounds, mainly of diterpene and phenolic nature, with only four compounds shared between the three species. Additionally, the extracts of the three salvias produced a significant antinociceptive effect at a dose of 300 mg/kg administered orally and did not present an acute oral toxicity effect at the maximum dose tested, indicating a parameter of LD50 > 2000 mg/kg. The exploration of the chemical profile of the three salvias by untargeted metabolomics shows that, despite being species with antinociceptive potential, they have different chemical profiles and therefore different active metabolites.
Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. Other radiation therapies include stereotactic body radiotherapy (SBRT) and proton could be administered.
Therapeutic preparations of living animal cells are prepared from the organs of foctal or sexually immature mammals by subjecting them to mechanical disintegration followed by digestion with ferments such as trypsin which removes connective tissue from the cells which remain living and unaltered.  The organ is disintegrated in contact with a liquid medium, for example, Hanks solution, trypsin (about 0.25%) is added and digestion allowed to continue at 37 DEG  C. until as much connective tissue as possible is digested whilst the cells remain living (about 5 to 10 minutes). Filtration gives a filtrate which is a suspension of cells in digestive fluid and a non-filterable portion which can be re-treated.  Further digestion in the filtrate is prevented by cooling in ice water and the filtrate is then centrifuged to give a deposit of cells which is washed free from digestive fluid and preferably also from necrotoxins.  The cells may then be introduced into ampoules, freeze dried until the moisture content is about 1 to 3% and stored or alternatively the cells may be suspended in physiological salt or Ringer's solution for injection. Differing species of cells from the same organ, having been freed from connective tissue may be separated for example by filtration or centrifugation.  Examples of organs from which preparations may be made according to the process include thyroid, pancreas, liver, spleen, hypophysis, ovary, the bulls' testicles. Specification 716,161 is referred to.
Participant will be assisted through the process by a therapist who will provide support and encouragement for 15-20 minutes of contact per week for the duration of the treatment. Supportive contacts are not psychotherapy. They are intended to answer questions about the content of the platform, to review adherence to the exercises and to provide encouragement; they also allow for the rapid identification and referral of participants in case of need (e.g., suicidal crisis).
Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
Post-operative breast pain is one of the most common adverse effects after breast surgery procedures. According to previous studies, anywhere from 20-60% of breast surgery patients report mastalgia as an adverse outcome of surgery (1, 2). Although the exact mechanism has not been well defined, the pain is generally neuropathic in nature and described as a burning sensation, electric and shock like, with a stabbing quality (2,3). The large majority of post-operative mastalgia is therefore believed to be secondary to nerve damage, particularly injury to the intercostobrachial nerve, and less commonly the long thoracic, medial and lateral pectoral, and/or the thoracodorsal nerves. Other reported causes of post-operative breast pain include scarring pain, lymphedema, radiation plexopathy, and hematomas (1-5).

Increasing rates of breast surgeries, whether elective, diagnostic, prophylactic, or therapeutic, warrant a more detailed examination of this pain-syndrome, particularly as previous research in the area is rather limited and narrow. A better understanding of the potential mechanisms causing pain, as well as more accurate and current incidence rates, and comparisons of adverse outcomes among the various options available to patients can help guide physicians towards improved clinical practices and patients towards more informed decision-making. Therefore, we designed this prospective cohort study to better understand the underlying mechanisms which may cause post-operative pain after various types of breast surgeries including breast biopsy, lumpectomy, mastectomy, mastectomy with reconstruction, cosmetic augmentation, and breast reduction, as well as to compare and contrast incidence, quality, and distribution of the post-operative pain caused by these various surgical procedures.
The present invention relates to a novel HER2 antibody for simultaneous administration used in preventing or treating cancer. The antibody of the present invention is an antibody which specifically bonds with HER2 which is over-expressed in cancer cells (especially, breast cancer cells and stomach cancer cells). The antibody of the present invention bonds with epitope separately from trastuzumab. Compared to the CDR sequences of the existing HER2 target antibodies, the antibody of the present invention has very low homogeny such that the sequence is peculiar. When the antibody of the present invention is simultaneously administrated with trastuzumab, cancer cells are killed by remarkably improved cancer cell killing functions, such that cancer (especially, breast cancer and stomach cancer) can effectively be prevented or treated. The excellence of simultaneous administration by the means of the antibody of the present invention is to control HER2 cooperatively with trastuzumab by bonding the antibody of the present invention with epitope on HER2 which is different from trastuzumab in a range which is not theoretically restricted (without wishing to be bound by theory).
Participants will get an exercise program, which is designed by their needs, desires and abilities. They will perform a desired exercise program 3 days a week and they will make an interview for motivation and/or modifying the program one day a week. They will write an activity diary.
The pathophysiology of pulmonary hypertension (PH) is not fully understood. Here, we tested the hypothesis that hypoxic perfusion of the vasa vasorum of the pulmonary arterial (PA) wall causes PH. Young adult pig lungs were explanted and placed into a modified ex vivo lung perfusion unit (organ care system, OCS) allowing the separate adjustment of parameters for mechanical ventilation, as well as PA perfusion and bronchial arterial (BA) perfusion. The PA vasa vasorum are branches of the BA. The lungs were used either as the control group (n = 3) or the intervention group (n = 8). The protocol for the intervention group was as follows: normoxic ventilation and perfusion (steady state), hypoxic BA perfusion, steady state, and hypoxic BA perfusion. During hypoxic BA perfusion, ventilation and PA perfusion maintained normal. Control lungs were kept under steady-state conditions for 105 min. During the experiments, PA pressure (PAP) and blood gas analysis were frequently monitored. Hypoxic perfusion of the BA resulted in an increase in systolic and mean PAP, a reaction that was reversible upon normoxic BA perfusion. The PAP increase was reproducible during the second hypoxic BA perfusion. Under control conditions, the PAP stayed constant until about 80 min of the experiment. In conclusion, the results of the current study prove that hypoxic perfusion of the vasa vasorum of the PA directly increases PAP in an ex situ lung perfusion setup, suggesting that PA vasa vasorum function and wall ischemia may contribute to the development of PH.NEW & NOTEWORTHY Hypoxic perfusion of the vasa vasorum of the pulmonary artery directly increased pulmonary arterial pressure in an ex vivo lung perfusion setup. This suggests that the function of pulmonary arterial vasa vasorum and wall ischemia may contribute to the development of pulmonary hypertension.
People infected with HIV have an increased risk for cardiovascular disease, which is a leading cause of death for those with HIV. This may be due to increased inflammation of the blood vessels, which is often observed in HIV-infected people and which can lead to endothelial dysfunction-a condition that involves the malfunctioning of the thin layer of cells that line the interior surface of blood vessels. Endothelial dysfunction increases the risk of developing both atherosclerosis and cardiovascular disease.

Much of the focus on the causes of HIV-related endothelial dysfunction has been centered on the use of several types of antiretroviral medications used to treat HIV infection. However, more recent data suggest that newer protease inhibitors, a type of antiretroviral medication, are not associated with endothelial dysfunction and that newer combination antiretroviral therapy (cART) regimens result in an initial improvement in endothelial dysfunction. Yet, preliminary research has also shown that in people who receive cART, the risk of endothelial dysfunction in fact persists with time, suggesting that a mechanism other than viral control, notably inflammation, is playing a role in endothelial dysfunction. Pentoxifylline is a medication that is currently used to reduce leg pain in people with blockages in the blood vessels in their legs. Previous research has shown that pentoxifylline may improve blood vessel function and reduce inflammation in people infected with HIV, but more research is needed to confirm these benefits. The purpose of this study is to compare the safety and effectiveness of pentoxifylline and cART versus cART alone at improving endothelial function and reducing inflammation in HIV-infected people.

This study will enroll people infected with HIV who are about to start receiving cART. At a baseline study visit, participants will undergo a medical history review; physical examination; measurements of blood pressure, heart rate, height, weight, temperature, waist, and hip; and blood and urine collection. An ultrasound imaging test of the arm will measure blood vessel function. Participants will then be randomly assigned to receive either pentoxifylline or placebo three times a day for 48 weeks. All participants will also receive cART medications, as prescribed by their primary HIV doctor. At study visits at Weeks 4, 8, 16, 24, 32, and 48, participants will undergo repeat baseline measurements; however, the ultrasound testing will only occur at Weeks 8, 24, and 48.
This is a Phase II study following up on a previous Phase I/II study in chemotherapy refractory metastatic disease with \<90 day survival expectancy. In the Phase I/II study all patients progressed using RECIST criteria. However, 11/42 (26%) were alive at 1yr and 9/42 (21%) alive at 2 yr. Therefore, CT scans did not correlate with clinical presentation and "pseudo-progression" was suspected. This study was designed to select subjects with visible tumor burden on the head, neck or tongue that could be measured and photographed so as not to rely solely on CT scans to determine anti-tumor debulking efficacy. Subjects are initially primed with intradermal AlloStim(TM) injections creating systemic anti-allo-specific cellular immunity. Tumor biopsy samples taken prior to dosing were processed into personalized Chaperone Rich Cell Lysate (CRCL) vaccine containing enriched heat shock proteins which are believed to chaperone tumor-specific neoantigens . AlloStim(TM) was then injected with CRCL into primed subjects to create tumor-specific cellular immunity. Subsequently, subjects are infused with intravenous AlloStim(TM) to cause extravasation of memory cells to the tumor lesions. The protocol including intradermal AlloStim(TM) day 0, 3, 7, 10. Intradermal AlloStim(TM)+CRCL on days 14, 17, 21, 24. Intravenous AlloStim(TM) day 28. This experimental treatment schedule will continue for 3 cycles.
Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), "Get your loved one sober: Alternatives to nagging, pleading and threatening" (Meyers \& Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills.
An array of multi-stage configured cleansing wipe products may include first stage cleansing wipes and second stage cleansing wipes. The first stage cleansing wipes may have a first structure and a first composition selected in view of a first child developmental stage. The second stage cleansing wipes may have a second structure and a second composition selected in view of a second child developmental stage. The first structure and the first composition are different and potentially progressive from first stage to second stage. First stage product packaging may include at least one first stage-specific indicia and second stage product packaging may include at least one second stage-specific indicia. Stages of the array may be communicated and tailored based upon the foods eaten and the manner of eating (such as being fed or self-feeding) of the babies or children in each stage.
Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
The invention relates to the use of at least folic acid or a folate and tetrahydrobiopterin (BH 4 ) or derivatives thereof for treating or preventing cardiovascular or neurological disorders by modulation of the activity of nitric oxide synthase (NOS). The present invention also relates to the use of at least folio acid or a folate and tetrahydrobiopterin (BH 4 ) or derivatives thereof for the production of a pharmaceutical preparation suitable for influencing the nitric oxide (NO) level, particularly by modulation of the activity of nitric oxide synthase (NOS) by reducing superoxide (O 2 .) production and enhancing nitric oxide (NO) synthesis. This effect occurs in absence of negative changes in other risk factors, e.g. lipids, blood pressure and homocysteine. Clinical areas of application include all anomalies of the nitric oxide level, particularly the prevention and treatment of cardiovascular and of neurological disorders. The present invention also relates to pharmaceutical preparations comprising at least one compound selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid or (6S)-tetrahydrofolic acid or pharmaceutically compatible salts thereof, together with tetrahydrobiopterin (BH 4 ) and with pharmaceutically compatible active and adjuvant substances, such as L-arginine, for influencing the nitric oxide (NO) level.